公开(公告)号：US20240109888A1

公开(公告)日：2024-04-04

申请号：US18347703

申请日：2023-07-06

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US11945834B2

公开(公告)日：2024-04-02

申请号：US16978208

申请日：2019-03-07

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Brian E. Fink ,  Zheming Ruan

IPC分类号： C07H21/02 ,  C07K16/28

CPC分类号： C07H21/02 ,  C07K16/2818

摘要： The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20240101666A1

公开(公告)日：2024-03-28

申请号：US18033200

申请日：2021-10-22

申请人： Bristol-Myers Squibb Company

发明人： Laurence David TOMS ,  Paul Andrew BASCIANO

IPC分类号： C07K16/28 ,  A61K31/282 ,  A61K31/337 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61K31/282 ,  A61K31/337 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/507

摘要： The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).

公开(公告)号：US20240066123A1

公开(公告)日：2024-02-29

申请号：US18336889

申请日：2023-06-16

申请人： Bristol-Myers Squibb Company

发明人： Lori S. BURTON ,  William Ying ,  Nils Lonberg ,  Sudhir Chakravarthi ,  Pedro Smith

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  C07K16/28

CPC分类号： A61K39/39591 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  A61J1/1412

摘要： This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.

公开(公告)号：US20240051996A1

公开(公告)日：2024-02-15

申请号：US17943532

申请日：2022-09-13

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Gardner S. CREECH ,  Mahboubeh KHEIRABADI ,  Martin D. EASTGATE ,  David S. NIRSCHL ,  Percy H. CARTER

IPC分类号： C07K7/64 ,  C07C309/75 ,  C07C309/77 ,  C07D225/08 ,  C07K1/04 ,  C07K1/107 ,  C07K17/08

CPC分类号： C07K7/64 ,  C07C309/75 ,  C07C309/77 ,  C07D225/08 ,  C07K1/042 ,  C07K1/1077 ,  C07K17/08

摘要： The disclosure is directed to the synthesis and improved methods for purifying macrocyclic peptides produced by solid phase peptide synthesis.

公开(公告)号：US20240050564A1

公开(公告)日：2024-02-15

申请号：US18271579

申请日：2022-01-07

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Yu LIU ,  Sarah TANNENBAUM-DVIR

IPC分类号： A61K39/395 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

CPC分类号： A61K39/3955 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

摘要： This disclosure provides combination therapy for treating a subject, such as a subject afflicted with lung cancer, such as small cell lung cancer, comprising administering to the subject various combinations of an anti-fucosyl-GM1 antibody, an immunomodulatory agent, such as a PD-1/PD-L1 antagonist, such as an antagonist anti-PD-1 or anti-PD-L1 antibody, carboplatin and etoposide.

公开(公告)号：US11884650B2

公开(公告)日：2024-01-30

申请号：US17743615

申请日：2022-05-13

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC分类号： C07D401/14 ,  C07D401/12

CPC分类号： C07D401/14 ,  C07D401/12

摘要： There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US11878975B2

公开(公告)日：2024-01-23

申请号：US16955097

申请日：2018-12-18

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  John L. Gilmore ,  Tasir Shamsul Haque ,  Trevor C. Sherwood ,  Brian K. Whiteley ,  Shoshana L. Posy ,  Sreekantha Ratna Kumar ,  Laxman Pasunoori ,  Srinivasan Kunchithapatham Duraisamy ,  Subramanya Hegde ,  Rushith Kumar Anumula ,  Pitani Veera Venkata Srinivas

IPC分类号： C07D471/08 ,  C07D487/08 ,  C07D519/00 ,  C07D471/04 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/02 ,  C07D487/04 ,  C07D491/08

CPC分类号： C07D471/04 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/02 ,  C07D487/04 ,  C07D491/08

摘要： Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20240002513A1

公开(公告)日：2024-01-04

申请号：US18251935

申请日：2021-11-05

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Leonard P. JAMES ,  Yougan CHENG ,  Brian J. SCHMDIT ,  John J. ENGELHARDT ,  Li LI

IPC分类号： C07K16/28

CPC分类号： C07K16/2818 ,  C07K2317/41 ,  A61K2039/545

摘要： The present invention provides methods of dosing and administration of non-fucosylated anti-CTLA-4 antibodies, such as non-fucosylated ipilimumab, as monotherapy, and related compositions and dosage forms.

公开(公告)号：US20240002512A1

公开(公告)日：2024-01-04

申请号：US18052076

申请日：2022-11-02

申请人： Bristol-Myers Squibb Company

发明人： John P. COGSWELL ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574

CPC分类号： C07K16/2818 ,  C07K16/2827 ,  A61K39/3955 ,  C07K16/18 ,  C07K16/2803 ,  G01N33/57492 ,  A61K2039/505

摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.